Evidence map›Paper›PMID 38378464›Full record

ArticleVirulence2024

Intranasal B5 promotes mucosal defence against Actinobacillus pleuropneumoniae via ameliorating early immunosuppression.

Jingsheng Huang, Weichao Kang, Dandan Yi, Shuxin Zhu, Yifei Xiang, Chengzhi Liu, Han Li, Dejia Dai, Jieyu Su, Jiakang He and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virulence, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Jingsheng HuangCollege of Animal Science and Technology, Guangxi University, Nanning, China.
Weichao KangCollege of Animal Science and Technology, Guangxi University, Nanning, China.
Dandan YiCollege of Animal Science and Technology, Guangxi University, Nanning, China.
Shuxin ZhuCollege of Animal Science and Technology, Guangxi University, Nanning, China.
Yifei XiangCollege of Animal Science and Technology, Guangxi University, Nanning, China.
Chengzhi LiuCollege of Animal Science and Technology, Guangxi University, Nanning, China.
Han LiCollege of Animal Science and Technology, Guangxi University, Nanning, China.
Dejia DaiCollege of Animal Science and Technology, Guangxi University, Nanning, China.
Jieyu SuCollege of Animal Science and Technology, Guangxi University, Nanning, China.
Jiakang HeCollege of Animal Science and Technology, Guangxi University, Nanning, China.
Zhengmin LiangCollege of Animal Science and Technology, Guangxi University, Nanning, China.ORCID 0000-0001-6473-4511
Guangxi University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Actinobacillus pleuropneumoniaeImmunity, InnateAnimalsCattleHumansImmunosuppression TherapyLungLymphocytesSwineTumor Necrosis Factor-alphaTumor Necrosis Factor-alphaActinobacillus pleuropneumoniaebovine neutrophil β-defensin-5Group 3 innate lymphoid cellsimmune suppressionmucosal defence

Identifiers

PMID38378464
PMCPMC10880497
OpenAlexW4392013216

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.